Browsing Tag
BeiGene
11 posts
Innovent Biologics secures FDA greenlight for first global Phase 3 trial of IBI363 in lung cancer
Innovent Biologics wins FDA approval for its first global Phase 3 trial of IBI363 in lung cancer, signaling a major milestone in immuno-oncology.
Glenmark Pharmaceuticals posts 12.8% revenue rise in FY25, beats market estimates
Glenmark Pharma posts ₹13,894 Cr profit in FY25. Explore its global growth, R&D breakthroughs, and why ISB 2001 may define its biotech future.
ImmunityBio, BeiGene launch Phase 3 Trial to advance lung cancer immunotherapy
ImmunityBio, Inc. (NASDAQ: IBRX) has entered into a collaboration and supply agreement with BeiGene, Ltd., a global oncology…
BeiGene stock surges on EU approval for TEVIMBRA in advanced cancer treatment
BeiGene, a global oncology company, announced that the European Commission has granted regulatory approval for TEVIMBRA (tislelizumab), its…
FDA approves BeiGene’s TEVIMBRA for esophageal cancer treatment
In a notable advancement in the oncology sector, BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a globally…
BeiGene’s BRUKINSA gains accelerated FDA approval for follicular lymphoma treatment
In a significant development for patients with relapsed or refractory follicular lymphoma, BeiGene, Ltd. has announced the U.S.…
CHMP recommends approval for BeiGene’s tislelizumab in ESCC treatment
BeiGene, a global biotechnology firm, has revealed that the European Medicines Agency’s (EMA) Committee for Medicinal Products for…
BeiGene gets Brukinsa FDA approval for chronic lymphocytic leukemia
BeiGene has secured the approval of the US Food and Drug Administration (FDA) for the company’s Brukinsa (zanubrutinib)…
Amgen secures breakthrough therapy designation for sotorasib in China
Amgen has achieved a major milestone in the global development of its investigational KRAS G12C inhibitor, sotorasib, with…
Chinese regulator accepts NDA of BeiGene’s pamiparib in ovarian cancer
BeiGene said that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has…